Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection

D Torre, F Speranza, R Martegani, D Torre, F Speranza, R Martegani

Abstract

In the last 10 years, interesting results have been reported concerning the impact of highly active antiretroviral therapy (HAART) on the changing pattern of organ-specific manifestations of HIV-1 infection. There has been a clear step-wise reduction in the incidence of several opportunistic infections (OIs), particularly Pneumocystis carinii pneumonia, whereas a nonsignificant reduction in incidence has been observed for other organ-specific diseases, including invasive cervical cancer and Hodgkin disease. In addition, several organ-specific manifestations, including HIV-associated nephropathy, wasting syndrome and cardiomyopathy, are a direct consequence of damage by HIV-1, and so HAART may have a therapeutic effect in improving or preventing these manifestations. Finally, the introduction of HAART has seen the emergence of several complications, termed immune reconstitution inflammatory syndrome, which includes OIs such as cytomegalovirus vitritis, Mycobacterium avium complex lymphadenitis, paradoxical responses to treatment for tuberculosis, and exacerbation of cryptococcosis. Because not all HIV-1 organ-specific manifestations are decreasing in the HAART era, this review will analyse the influence of HAART on several organ-specific manifestations, and in particular OIs related to several organs, cerebral disorders and HIV-1-related neoplasia.

References

    1. Kaplan JE, Hanson D, Dworkin MS et al Epidemiology of human immunodeficiency virus‐associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5–S14.
    1. Deeks SG, Hecht FM, Swanson M et al HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35–F43.
    1. Forrest DM, Seminari E, Hogg RS et al The incidence and spectrum of AIDS‐defining ilnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998; 27: 1379–1385.
    1. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415–418.
    1. Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS‐defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001; 42: 134–139.
    1. Shelburne SA, Hamill RJ, Rodriguez‐Barradas MC et al Immune reconstitution inflammatory syndrome. Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81: 213–227.
    1. Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV‐infected persons. J Acquir Immune Defic Syndr 1999; 21: S11–S17.
    1. Torres RA, Baney M, Barr MR. Stabilization of in‐patient daily census despite continued reduction in HIV‐related admission at a New York City hospital. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February, 1998 [Abstract 203].
    1. Detels R, Tarwater P, Phair JP et al Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 16: 347–355.
    1. Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM. Impact of highly active antiretroviral therapy on individual AIDS‐defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 2002; 29: 388–395.
    1. Lederberger B, Egger M, Erard V et al AIDS‐related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV Cohort Study. J Am Med Assoc 1999; 282: 2220–2226.
    1. Perez‐Olmeda M, Machuca A, Garcia‐Samaniego J, Soriano V. HAART does not modify HCV replication in HIV‐HCV coinfected patients. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, January–February 1999 [Abstract 193].
    1. Tor J, Tural C, Ojanguren I et al Histological damage of hepatitis C in HIV‐infected patients. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January–February 1999 [Abstract 192].
    1. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120: 1888–1893.
    1. De Gaetano Donati K, Bertagnolio S, Tumbarello M et al Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV‐infected subjects. Int J Antimicrob Agents 2000; 16: 357–360.
    1. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV‐associated tuberculosis in the era of highly active antiretroviral therapy. The adult/adolescent spectrum of HIV disease group. Int J Tuberc Lung Dis 2000; 4: 1026–1031.
    1. Bower M, Powles T, Nelson M et al HIV‐related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 14: 371–375.
    1. Brodt HR, Kamps BS, Gute P et al Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731–1738.
    1. Michaels J and the Adult Spectrum of Disease Cohort. Opportunistic incidence rates from the Tulane/adult spectrum of disease cohort, 1994–98. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA, Chicago, IL, February 1998 [Abstract 325].
    1. Janssen RS. Epidemiology and neuroepidemiology of human immunodeficiency virus infection, In: Berger JR, Levy RM, eds. AIDS and the Nervous System, 2nd edn Philadelphia, Lippincott‐Raven; 1997: 13–37.
    1. Neuenburg JK, Brodt HR, Herndier BG et al HIV‐related neuropathology, 1985–99: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171–177.
    1. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus‐infected patients before and during the highly active antiretroviral therapy. Clin Infect Dis 2001; 33: 1747–1755.
    1. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy. J Neurol Neurosurg Psychiatry 2000; 69: 376–380.
    1. Masliah E, DeTeresa RM, Mallory ME et al Changes in pathologic findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14: 69–74.
    1. Gendelman HE, Zheng J, Coulter CL et al Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus‐associated dementia. J Infect Dis 1998; 178: 1000–1007.
    1. Markus R, Brew BJ. HIV‐1 peripheral neuropathy and combination antiretroviral therapy. Lancet 1998; 352: 1906–1907.
    1. Ammassari A, Cingolani A, Pezzotti P et al AIDS‐related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55: 1194–1200.
    1. Hoffmann C, Tabrizian S, Wolf E et al Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART‐induced immune recovery. AIDS 2001; 15: 2119–2127.
    1. Cinque P, Pierotti C, Vigano MG et al The good and evil of HAART in HIV‐related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7: 358–363.
    1. Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1‐infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35: 1250–1257.
    1. Sewell D. Schizophrenia and HIV. Schizophren Bull 1996; 22: 465–473.
    1. Torre D, Fraticelli C, Gualandi E, Gambarini S, Tambini R. Impact of HAART on acute psychosis patients with AIDS. XIV International AIDS Conference. Barcelona, July 2002, 327–330.
    1. De Castro S, Migliau G, Silvestri A. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 1992; 13: 1452–1459.
    1. Corallo S, Mutinelli MR, Moroni M et al Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur Heart J 1998; 9: 887–892.
    1. Hsia J, Ross AM. Pericardial effusion and pericardiocentesis in human immunodeficiency virus infection. Am J Cardiol 1994; 74: 94–96.
    1. Acierno LJ. Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review. J Am Coll Cardiol 1989; 17: 1144–1154.
    1. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV‐positive patients with cardiac involvement. J Infect 2000; 40: 282–284.
    1. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31: 787–797.
    1. Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV‐1 infection? J Acquir Immune Defic Syndr 2002; 30: 471–477.
    1. Rickerts V, Brodt H, Staszewski S et al Incidence of myocardial infarctions in HIV‐infected patients between 1983 and 1998: the Frankfurt HIV-cohort. Eur J Med Res 2000; 5: 329–333.
    1. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702–710.
    1. Holmberg SD, Moorman AC, Williamson JM et al Protease inhibitors and cardiovascular outcomes in patients with HIV‐1. Lancet 2002; 360: 1747–1748.
    1. Friiss‐Moller N, Weber R, Reiss P et al Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179–1193.
    1. Winston J, Klotman PE. Are we missing an epidemic of HIV‐associated nephropathy? J Am Soc Nephrol 1996; 7: 1–7.
    1. US Renal Data System (USRDS). USRDS 1998 Annual Data Report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, National Health Institutes; 1998.
    1. Connolly JO, Weston Ce Hendry BM. HIV‐associated renal disease in London hospitals. Q J Med 1995; 88: 627–634.
    1. Mattana J, Siegal FP, Schwartzwald E et al AIDS‐associated membranous nephropathy with advanced renal failure: response to prednisone. Am J Kidney Dis 1997; 30: 116–119.
    1. Nochy D, Glotz D, Dosquet P et al Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993; 8: 11–19.
    1. Michel C, Dosquet P, Ronco P, Mongenot B, Viron B, Mignon E. Nephropathy associated with human immunodeficiency virus: a report of 11 cases including 6 treated with zidovudine. Nephron 1992; 62: 434–440.
    1. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV‐1‐associated nephropathy and response to highly‐active antiretroviral therapy. Lancet 1998; 352: 783–784.
    1. Dellow E, Unwin R, Miller R, Williams I, Griffiths M. Protease inhibitor therapy for HIV infection: the effect of HIV-associated nephrotic syndrome. Nephrol Dial Transplant 1999; 14: 744–747.
    1. Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001; 33: 115–119.
    1. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE. Nephropathy in human immunodeficiency virus‐1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100: 84–92.
    1. Perinbasekar S, Brod‐Miller C, Pal S, Mattana J. Predictors of survival in HIV‐infected patients on hemodialysis. Am J Nephrol 1996; 16: 280–286.
    1. Schwartz EJ, Szczech L, Winston AJ, Klotman PE. Effect of HAART on HIV‐associated nephropathy (abstract A0882). J Am Soc Nephrol 2000; 11: 165a.
    1. Olyaei AJ, De Mattos AM, Bennett WM. Renal toxicity of protease inhibitors. Cur Opin Nephrol Hypertens 2000; 9: 473–476.
    1. Karras A, Lafaurie M, Furco A et al Tenofovir‐related nephrotoxicity in human immunodeficiency virus‐infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070–1073.
    1. Lane GP, Lucas CR, Smalwood RA. The gastrointestinal and hepatic manifestations of the acquired immune deficiency syndrome. Med J Aust 1989; 150: 139–143.
    1. Monkemuller KE, Wilcox CM. Diagnosis and treatment of colonic disease in AIDS. Gastrointest Endosc Clin North Am 1998; 8: 889–891.
    1. Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am J Gastroenterol 2000; 95: 457–462.
    1. Pollok RC. Viruses causing diarrhoea in AIDS. Novartis Found Symp 2001; 238: 276–283.
    1. Nelson MR, Shanson DC, Hawkins DA et al Salmonella, Campylobacter and Shigella in HIV‐seropositive patients. AIDS 1992; 6: 1495.
    1. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV‐1‐associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351: 256–261.
    1. Miao YM, Awad‐El‐Kariem FM, Franzen C et al Eradication of cryptosporidia and microsporida following successful antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 25: 124–129.
    1. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the intial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407–414.
    1. Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control 2000; 28: 262–266.
    1. Poles MA, Dieterich DT, Schwarz ED et al Liver biopsy findings in 501 patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 170–177.
    1. Bodsworth N, Donovan B, Nightgale B. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160: 577–582.
    1. Eyster ME, Diamondstone LS, Lien JM, Ehman WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused haemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6: 602–610.
    1. Den Brinker M, Wit FW, Wertheim‐van Dillen PM et al Hepatitis B and C virus coinfection and the risk for hepatoxicity of highly active antiretroviral therapy in HIV‐1 infection. AIDS 2000; 14: 2895–2902.
    1. Manegold C, Hannoun C, Wywiol A et al Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 144–148.
    1. Soto B, Sanchez‐Quijano A, Rodrigo L et al Human immunodeficiency virus infection modifies the natural history of chronic parenterally‐acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1–5.
    1. Zylberberg H, Chaix ML, Rabian C et al Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998; 26: 1104–1106.
    1. Gavazzi G, Richallet G, Morand P et al Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV. Pathol Biol 1998; 46: 12–15.
    1. Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients with highly active antiretroviral therapy. Clin Infect Dis 2001; 33: 1579–1585.
    1. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 783–785.
    1. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in haemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180: 2027–2029.
    1. Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus‐coinfected patients. J Virol 2003; 77: 1940–1950.
    1. Fialaire P, Payan C, Vitour D et al Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999; 180: 574–575.
    1. Yokozaki S, Takamatsu J, Nakano I et al Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96: 4293–4299.
    1. Ramirez‐Amador V, Esquivel‐Pedraza L, Sierra‐Madero J, Anaya‐Saavedra G, Gonzalez‐Ramirez I, Ponce de Leon S. The changing clinical spectrum of human immunodeficiency virus (HIV)‐related oral lesions in 1,000 consecutive patients: a 12-year study in a referral center in Mexico. Medicine 2003; 82: 39–50.
    1. Ceballos‐Salobrena A, Gaitan‐Cepeda LA, Ceballos‐garcia L, Lezama‐del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 2000; 14: 627–635.
    1. Smith C, Lilly S, Mann KP et al AIDS‐related malignancies. Ann Med 1998; 30: 323–344.
    1. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus‐infected adults. J Natl Cancer Inst 2000; 92: 1823–1830.
    1. Ledergerber B, Telenti A, Egger M. Risk of HIV‐related Kaposi's sarcoma and non‐Hodgkin lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999; 319: 23–24.
    1. Levine AM, Tulpule A. Clinical aspects and management of AIDS‐related Kaposi's sarcoma. Eur J Cancer 2001; 37: 1288–1295.
    1. Sgadari C, Barillari G, Toschi E et al HIV protease inhbitors are potent anti‐angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med 2002; 8: 225–232.
    1. Patton LL, McKaig R, Strauss R et al Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299–304.
    1. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly antiretroviral therapy on frequency of oral warts. Lancet 2001; 357: 1411–1412.
    1. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus‐associated oral warts among human immunodeficiency virus‐seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34: 641–648.
    1. Tappero JW, Perkins BA, Wenger JD, Berger TG. Cutaneous manifestations of opportunistic infections in patients with human immunodeficiency virus. Clin Microbiol Rev 1995; 8: 440–450.
    1. Kreuter A, Schugt I, Hartmann M, Rasokat H, Altmeyer P, Brockmeyer NH. Dermatological diseases and signs of HIV infection. Eur J Med Res 2002; 7: 57–62.
    1. Calista D, Morri M, Stagno A, Boschini A. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. Am J Clin Dermatol 2002; 3: 59–62.
    1. Pepose JS, Holland GN, Nestor MS et al Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985; 92: 472–484.
    1. Morinelli EN, Dugel PU, Lee M et al Opportunistic intraocular infections in AIDS. Trans Am Ophthalmol Soc 1992; 90: 97–108.
    1. Jalali S, Reed JB, Mizoguchi M, Flynn N, Gordon J, Morse LS. Effect of highly active antiretroviral therapy on the incidence of HIV‐related cytomegalovirus retinits and retinal detachment. AIDS Patient Care STDS 2000; 14: 343–346.
    1. Lin DY, Warren JF, Lazzeroni LC, Wolitz RA, Mansour SE. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors. Retina 2002; 22: 268–277.
    1. Deayton JR, Wilson P, Sabin CA et al Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14: 1163–1170.
    1. Chang Y, Cesarman E, Pessin MS et al Identification of herpsevirus‐like DNA sequences in AIDS‐associated Kaposi's sarcoma. Science 1994; 266: 1865–1869.
    1. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Defic Syndr 2003; 32: 527–533.
    1. Ratner L, Lee J, Tang S et al Chemotherapy for HIV associated non‐Hodgkin lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171–2178.
    1. Glaser S, Clarke CA, Gulley ML et al Population‐based patterns of human immunodeficiency virus‐related Hodgkin lymphoma in the greater San Francisco bay area, 1988–98. Cancer 2003; 98: 300–309.
    1. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV‐seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 1459–1464.
    1. Lillo FB, Ferrari D, Veglia F et al HPV infection and associated cervical disease in HIV infected women: effect on highly active antiretroviral therapy. J Infect Dis 2001; 184: 547–551.
    1. De Gaetano Donati K, Tumbarello M, Tacconelli E et al Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV‐1 infected subjects. J Chemother 2003; 15: 60–65.
    1. Chang L, Ernst T, Witt MD et al Persistent brain abnormalities in antiretroviral‐naïve HIV patients 3 months after HAART. Antivir Ther 2003; 8: 17–26.
    1. McCormack JG, Bowler SD, Donnelly JE, Steadman C. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 1998; 26: 1008–1009.
    1. Postelmans L, Payen MC, De Wit S, Caspers‐Velu L. Neovascularization of the optic disc after highly active antiretroviral therapy in an AIDS patient with cytomegalovirus retinitis. A new immune recovery‐related ocular disorder? Ocular Immunol Inflamm 1999; 7: 237–240.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe